All Industries

Willow Bioscience Announces 3 Million dollar Fundraising to Support Partnership with Laurus Labs

Willow Biosciences Inc.

Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to share the company's plans to raise approximately $3 million. This capital will be used to support Willow Bioscience's recent partnership announcement with Laurus Labs. Dr. Savile explained that the deal with Laurus is a multi-product development and licensing partnership with a leading research-driven pharmaceutical and biotechnology company. Laurus Labs, with a market cap of $3.9 billion, serves global pharmaceutical companies and offers Contract Development and Manufacturing Organization (CDMO) services. Since its inception, Laurus has commercialized over 80 products and operates nine manufacturing facilities, including those with fermentation capabilities. Willow Bioscience aims to leverage its AI-driven technology platform and extensive expertise in enzyme, strain, and process engineering to develop biobased processes for high-value Active Pharmaceutical Ingredients (APIs). This includes Willow’s BioOxi™-based corticosteroid processes, intended for large-scale manufacturing, sales, and distribution at Laurus Labs. The first programs from this partnership are expected to reach commercial manufacturing by 2025. The planned fundraising will provide the necessary capital to advance these initiatives, ensuring that Willow Bioscience can effectively collaborate with Laurus Labs to bring innovative biobased pharmaceutical solutions to the market. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

June 07, 2024 12:27 PM Eastern Daylight Time

Video

News Release

Horizon Copper CEO Discusses Strategic Portfolio Expansion and Future Plans

Horizon Copper Corp

Horizon Copper CEO Erfan Kazemi joined Steve Darling from Proactive to share insights into the company's robust portfolio and strategic future plans, emphasizing a focus on copper assets. Horizon Copper is dedicated to building a strong portfolio of copper projects. The company currently holds interests in three major copper assets. One of their notable investments includes a 1.7% stake in the Antamina mine, which is the third-largest copper mine globally. This asset is not only generating cash flow but also recently had its mine life extended by over a decade. The approval of Antamina's Environmental Impact Assessment (EIA) could potentially further boost its cash flow. Another significant asset in Horizon Copper's portfolio is its interest in the Oyu Tolgoi mine, which is anticipated to become the fourth-largest copper mine in the world. This project is expected to start generating cash flow by 2027, with long-term production forecasts spanning several decades. Horizon Copper's third key asset is the Hod Maden project, which is notable for its discovery and is expected to enter commercial production within a few years. Kazemi emphasized Horizon Copper's strategy of partnering with large, reputable companies like Rio Tinto to diversify and expand their portfolio continuously. The company is also actively seeking new acquisitions to ensure steady, long-term returns for its shareholders. Contact Details Proactive North America +1 604-688-8158 na-editorial@proactiveinvestors.com

June 07, 2024 12:07 PM Eastern Daylight Time

Video

Loneliness Crisis Being Faced by Older Americans: AmeriCorps Seniors Believes Volunteering Fosters Connections and Conquers Loneliness

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/dcH7-VsQaYQ Older adults are especially vulnerable to loneliness and social isolation, which can have a serious effect on health, according to a recent report issued by the U.S. Surgeon General. Chronic loneliness (persistent feelings of isolation and/or a lack of companionship) can adversely affect mental, cognitive, and physical health, general well-being and even longevity. However, there are ways to overcome loneliness and volunteering might be the answer. AmeriCorps Seniors is helping older adults form connections in their community, provide purpose and improve their lives through volunteering. After two years of volunteering with AmeriCorps Seniors, 78% of those who reported more than five symptoms of depression at the beginning of the study said that they felt less depressed two years later. Of those who first described a lack of companionship, 88% said they felt less isolated after two years. AmeriCorps is the federal agency for national service and volunteerism. AmeriCorps Seniors focuses on engaging adults ages 55 and up in service in their local communities. Through three signature programs, RSVP, the Foster Grandparent Program and the Senior Companion Program, AmeriCorps Seniors provides a space for older adults to take charge of this moment in life and use their time in impactful ways. Each year, AmeriCorps Seniors matches more than 140,000 Americans with service opportunities. For example, Shelley Brosnan, a volunteer with AmeriCorps Seniors RSVP through Volunteer Fairfax, Fairfax, Va., said, “Giving back is so very important. I’ve been volunteering for most of my adult life. Volunteering allows me to connect with my community and make it a better place. I also love the social aspects and meeting people who share my interests. We have a chance to help others and form new relationships, which has grown my social circle.” RSVP offers flexible scheduling and a diverse mix of opportunities. The Foster Grandparent Program pairs volunteers with children and youth in mentoring and tutoring relationships. Lastly, the Senior Companion Program provides a helping hand to other older adults and those with disabilities. They also support caregivers through respite services. For more information and to find volunteer opportunities near you, visit AMERICORPS.GOV/YOURMOMENT. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

June 07, 2024 12:06 PM Eastern Daylight Time

Video

EuroPacific Metals Announces Amended Earn-In Agreement for Barrancos Copper-Gold Project

Europacific Metals Inc

EuroPacific Metals CEO Karim Rayani joined Steve Darling from Proactive to announce an amendment to the company's earn-in and partnership agreement with BMP Holding and Indice Crucial Lda for the Barrancos copper-gold project. This project comprises the Aparis Copper mine and the Lirio gold project, along with advanced exploration applications for the Bigorne and Vilariça copper-gold projects in northern Portugal. Rayani explained that the revised agreement allows for more funds to be directed towards ground operations. Under the new terms, EuroPacific Metals will pay BMP €15,000 in cash, issue 500,000 ordinary shares, and provide 500,000 warrants at 7.5 cents over five years to secure a 60% stake in Indice Crucial Lda (ICL). An additional cash transfer of €15,000 within the next three months will increase their participation to 80%. To acquire the remaining 20% and achieve 100% ownership of ICL, EuroPacific Metals must pay BMP €800,000 within five years of obtaining a mining license, with half paid in cash and the other half in EuroPacific shares. This new, more favorable deal structure aims to ensure that a greater portion of funds are allocated to on-ground exploration and development, enhancing the potential success of these promising copper-gold projects. Contact Details Proactive North America +1 604-688-8158 na-editorial@proactiveinvestors.com

June 07, 2024 12:04 PM Eastern Daylight Time

Video

HTX Maximizes Your Earning Potential with Simple Earn and Shark Fin Products: Timely Listings and High APYs

HTX

As the spot Ethereum ETF receives approval, Bitcoin surpasses $70,000, and popular meme coins continue to emerge, the cryptocurrency market is signaling the start of a bull run. According to CoinMarketCap data, spot trading volume and futures open interest have been climbing in recent days. Accordingly, crypto earning products often provide higher annualized returns than usual, making them a crucial avenue for investors to boost their yields beyond trading. However, with a wide variety of crypto earning products available in the market, how can investors find the most suitable options? Now, let's turn our attention to the lucrative products of Simple Earn and Shark Fin, designed by HTX, the world-leading crypto exchange, to meet the investment needs of different users. Simple Earn: Trend-Following Listings HTX not only ensures high quality and fast listing of new coins but also keeps its Earn products updated with the market trends. According to HTX's official announcements, the latest additions to its Flexible products include BB, a favorite in the Restaking sector, and trending meme coins, such as GME, SLOTH, and MAGA, granting users up to 10% APY. Currently, the Flexible products feature more than 30 popular assets, including PEPE, BOME, MERL, and WIF, allowing users to enjoy the appreciation of these quality cryptocurrencies while harvesting extra rewards. Additionally, these products support instant subscriptions and redemptions for flexibly allocating assets with the best investment opportunities. Subscription is easy: for web clients, simply log in to the HTX platform and select Earn > Flexible/Fixed from the top navigation bar; for app clients, access Earn > Simple Earn on the homepage. Shark Fin: High Basic APY Shark Fin products are offered by many exchanges, but HTX stands out with its attractive basic APY. As of press, HTX’s 7-day Shark Fin APY ranges from 5.5% to 35%, where each individual can make a subscription of up to 3 million USDT; the 3-day Shark Fin APY from 5.5% to 30%. In comparison, a leading exchange’s 7-day and 3-day Shark Fin APYs range only 5.5%-15% and 1%-6%, respectively. Already, HTX has issued 38 rounds of 7-day Shark Fin and 25 rounds of 3-day Shark Fin, with a total subscription amount reaching $2 billion. Besides high returns, HTX’s Shark Fin boasts an Auto Reinvest feature for effortless subscriptions. With this feature enabled easily, investments in both 3-day and 7-day products can be automatically re-invested into the corresponding 7-day products, making your funds work till you drop for return maximization. Moreover, subscribing to both the bullish and bearish products of the same cryptocurrency will reward you with up to 10% APY, 4% higher than the basic APY. To make subscriptions, go to the Earn page when the subscription is open, click on Structured Products, and select Shark Fin. About HTX Founded in 2013, HTX has evolved over a decade from a simple cryptocurrency exchange to a comprehensive blockchain business ecosystem. This expansion covers a wide range of services including digital asset trading, financial derivatives, wallets, research, investments, incubation, and more. As a world-leading portal to Web 3.0, HTX is committed to a growth strategy focused on global expansion, ecological prosperity, wealth effect, and safety and compliance. This approach enables us to offer comprehensive, safe, and reliable services and value to virtual currency enthusiasts around the world, reinforcing our position as a global gateway to Web3. Contact Details Michael Wang glo-media@htx-inc.com Company Website https://www.htx.com/

June 07, 2024 11:41 AM Eastern Daylight Time

HTX Shines at GM Vietnam 2024 and Hosts Web3 Future Night: Spotlighting Crypto Trends, Advancing Global Expansion

HTX

HTX, the world-leading crypto exchange, made a noteworthy appearance at GM Vietnam 2024 as a gold sponsor on June 7. This strategic move marks a significant step in HTX's global expansion efforts, as close connections and cooperations were formed with local blockchain startups, tech teams, and the crypto communities to drive technological innovation and contribute to the growth of the blockchain ecosystem, both in Vietnam and globally. At the event, HTX's booth G6 attracted widespread attention and active engagement from attendees. Additionally, Amelia Chan, head of strategic partnerships at HTX, was invited to participate in a roundtable discussion, themed "Importance of Liquidity in Digital Assets Markets". Chan dived into the measures exchange venues employ to ensure a constant stream of asset flows. Crypto markets are volatile and susceptible to large price swings and abnormal conditions. Chan stated that as a well-established large centralized exchange, HTX has mature experience and resources in dealing with such situations. "We ensure the safety of user assets on the platform, and we maintain a 100% reserve fund to cope with extreme situations. We have implemented powerful risk management systems that monitor market conditions in real-time and identify potential risks," she said. She also highlighted HTX's strict measures in response to extreme conditions, such as price fluctuations, to ensure user asset security. HTX is committed to providing a safe and reliable user experience and continuously monitors and adapts to changing market dynamics. In terms of using digital asset platforms, Chan provided several reminders including enabling two-factor authentication, awareness of phishing websites, staying informed about market dynamics, as well as cautious and diversified investments. Another highlight was the "Web3 Future Night" event held by HTX in Ho Chi Minh City on June 6, in collaboration with well-known media outlet ChainCatcher. The party, buzzing with energy and optimism, brought together Vietnam’s most active crypto KOLs and community members, charting a promising future for Vietnamese Web3 enthusiasts and practitioners. Speakers from HTX, ChainCatcher, LBank, 4E, GoPlus, SOEX, and BTC Beta shared their insights and forward-thinking perspectives on the Web3 industry. GM Vietnam 2024, held from June 7 to 8 in Ho Chi Minh City, gathered globally renowned crypto projects, investors, entrepreneurs, and tech experts to discuss the latest trends and uncover new growth opportunities in the market. HTX has set its sights on the Vietnamese Web3 markets. The move comes amidst a surge of Web3 projects in Vietnam, sparked by wildly popular Axie Infinity in 2021 and subsequently influential startups like Yield Guild Games (YGG) and Ancient 8. That's why Vietnam is rapidly becoming a focal point for the Web3 ecosystem in Asia. HTX holds long-standing interest and support for cutting-edge sectors like meme coins, blockchain gaming, and social finance, and is well-positioned to capitalize on this trend with its efforts to increase user base in Vietnamese markets. The exchange anticipates collaborating with Vietnamese users to explore the crypto infinity. About HTX Founded in 2013, HTX has evolved over a decade from a simple cryptocurrency exchange to a comprehensive blockchain business ecosystem. This expansion covers a wide range of services including digital asset trading, financial derivatives, wallets, research, investments, incubation, and more. As a world-leading portal to Web 3.0, HTX is committed to a growth strategy focused on global expansion, ecological prosperity, wealth effect, and safety and compliance. This approach enables us to offer comprehensive, safe, and reliable services and value to virtual currency enthusiasts around the world, reinforcing our position as a global gateway to Web3. Contact Details Michael Wang glo-media@htx-inc.com Company Website https://www.htx.com/

June 07, 2024 11:38 AM Eastern Daylight Time

SMC Enters into Acquisition Agreement to Purchase 100% of the Assets of ChainTrade Ltd. Launches AI-Powered Research Platform.

SMC Entertainment, Inc.

Boca Raton, FL - June 7, 2024 - SMC Entertainment, Inc. ("SMC" or the "Company") (OTC: SMCE), a versatile incubator company focused on acquisition and support of proven commercialized financial services and technology (Fintech) companies, is excited to announce the launch of the Chaintrade AI powered research platform and that the Company has entered into an Acquisition Agreement to acquire 100% of the assets of ChainTrade Ltd.’s AI-powered Trading Platform (the “Platform”). The closing of the Acquisition is pending the completion of customary due diligence, which is expected to be completed within 30 days Chaintrade is a Joint Venture between Plato Data Intelligence and Redmatter.Capital. and was built to revolutionize trading and investing by leveraging AI's predictive capabilities. ChainTrade, is a UK-registered Fintech company. Chaintrade has developed a Platform to allow users to trade Equities, ETFs, Commodities, and Indices with the support of a personalized AI-powered trading assistant. The Platform was built to revolutionize trading and investing by leveraging AI's predictive capabilities. This will improve research, risk management and asset allocation. The Platform provides the user personalized and customized investment strategies and utilizes AI to evaluate assets within a portfolio. The launch of the AI research tool will enable investors to analyze thousands of data points including live price data, performance, investor sentiment, fair value, and risk factors simultaneously. These enable The ChainTrade AI Research tool to provide insights, enabling investors to make informed decisions to optimize their portfolio performance. ChainTrade and its founding members have spent the last three years building the required infrastructure to deploy it to the market. Once fully enabled the platform will be able to facilitate all transactions in a highly secured environment. The Platform’s development and features continue to evolve so it can be marketed across emerging markets. “I want to thank our shareholders for being patient with the management team. We continue to work towards the development of our vision for the company. With the pending acquisition of Chaintrade AI our vision is now on a solid executable foundation.” quoted Erik Blum, Chairman & CEO of SMC. “With the launch of the Chaintrade AI Research Tool we have another foundation block in place. We plan to deploy a fully functioning AI enhanced SaaS model to market by the end of the quarter. As well we will continue to build on the platform both organically and through acquisition. We have developed a very strong team internally which we believe can enhance our platform and increase our shareholder value We expect to see positive revenue growth from the acquisition quickly. Nobody else can do what we do, we intend on being the best in class, what every other platform is measured against. This is an extremely exciting time for the company, and I look forward to executing on plan and uplisting to a senior exchange We are planning on providing a complete shareholder update within the next few weeks.” Prem Couture / Founder of Redmatter Capital: “We have developed a specialized language model tailored specifically for finance, with a focus on stocks, companies, revenue statements, balance sheets, and cash flow. This advanced model is adept at retrieving and analyzing data from live data feeds, providing real-time insights and analysis for financial professionals and investors. We have spent the last 3 years building our infrastructure around facilitating both OnChain and Offchain transactions in a highly secured environment.” Bryan Feinberg, Founder of Plato Data Intelligence: “As the underlying technologies we are developing continue to evolve, we can play in making AI more accessible to everyone, especially across emerging markets.” About SMC: https://smceinc.com SMC is a versatile holding company focused on acquisition and support of proven commercialized financial services and technology (Fintech) companies. SMC's multi-discipline growth by acquisition approach is to enhance revenues and shareholder equity. About Chaintrade: https://chaintrade.ai Chaintrade LTD is a UK Registered Entity and is affiliated with Red Matter Capital LTD a registered financial service company, with its subsidiary licensed under a securities trading license granted by the Montenegro Capital Market Authority (CMA) Authorized by the law on capital markets by the government of Montenegro. Safe Harbor Statement Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets, and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements. The Company does not make any representation or warranty, express or implied, regarding the accuracy, completeness, or updated status of such forward-looking statements or information provided by the third-party. Therefore, in no case whatsoever will the Company and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or any related damages. Contact Details SMC Entertainment, Inc. Erik Blum / CEO +1 360-820-5973

June 07, 2024 09:45 AM Eastern Daylight Time

Image

Nickel - The Unsung Hero Powering The Green Revolution?

Benzinga

By Johnny Rice, Benzinga Nickel is a critical component of many modern technologies and with the recent discovery that adding more nickel to EV batteries increases their drivable range, energy transition-related demand for this critical mineral may increase nearly significantly over the coming decades. Sprott Asset Management, a leader in critical mineral investing, offers the Sprott Nickel Miners ETF (NASDAQ: NIKL). The ETF seeks to provide investment results that generally correspond to the total return performance of the Nasdaq Sprott Nickel Miners™ Index, an index designed to track the performance of a selection of global securities in the nickel industry, including nickel producers, developers and explorers. NIKL can provide exposure for investors looking to ride the green wave. Learn more here: Featured photo by Paul-Alain Hunt on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

June 07, 2024 09:00 AM Eastern Daylight Time

Video Image

Theriva Biologics Receives Fast Track Designation From FDA For VCN-01 For Treating Metastatic Pancreatic Cancer

Benzinga

By Kyle Anthony, Benzinga Theriva™ Biologics (AMEX: TOVX) is an immuno-oncology company developing oncolytic viruses, otherwise known as cancer cell-infecting viruses, to overcome the protective barrier surrounding solid tumors and selectively kill tumor cells. As a company engaged in developing differentiated clinical-stage therapeutics, Theriva’s mission is to change patient outcomes by working to improve the current standard of care and transform the cancer therapy landscape. The firm’s management and scientific advisory board is comprised of determined and experienced leaders who are committed to offering patients with difficult-to-treat cancers the chance of a longer life. The company recently achieved a significant milestone as the U.S. FDA granted Fast Track Designation (FTD) to its candidate VCN-01 to improve progression-free survival and overall survival in patients with metastatic pancreatic adenocarcinoma. Previously, the FDA granted orphan drug designation to VCN-01 for treatment of pancreatic ductal adenocarcinoma (PDAC). Company Background Founded in 2001 and operating as Synthetic Biologics from 2012, the company was previously focused on developing biologic and drug candidates for various indications, including infectious diseases and gastrointestinal disorders. The company rebranded to Theriva Biologics in September 2022 to reflect its evolving focus on oncolytic viruses and cancer therapies. Regarding the impetus behind the firm’s rebranding, Steven A. Shallcross, Chief Executive Officer of Theriva Biologics, said, “The rebranding solidifies our strategic transformation and reflects our sharpened focus on advancing unique, oncolytic viruses optimized for IV administration. We continue to build on the incredible progress made to date and are diligently advancing our oncolytic adenovirus pipeline. This includes lead clinical-stage program VCN-01, designed to break down the tumor stroma, and preclinical-stage program VCN-11, leveraging our proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. These two differentiated programs are intended to improve the anti-tumor effect of the oncolytic virus, co-administered chemotherapies and/or immuno-oncology therapeutics. Together, VCN-01 and VCN-11 position Theriva at the forefront of oncolytic virus development. We are excited about Theriva’s path towards strategic growth, renewed corporate strategy and remain on track to deliver on upcoming value-driving milestones.” Theriva Biologics Pipeline As Steven A. Shallcross’s preceding quote suggests, Theriva Biologics' leading clinical-stage program, VCN-01, has displayed promise as a treatment solution. Presently, VCN-01 is part of an ongoing phase 2 clinical trial, entitled VIRAGE, where it is being tested in combination with standard-of-care chemotherapy for patients with pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer. VCN-01 was also administered with the checkpoint inhibitor durvalumab (an FDA-approved immunotherapy for cancer) in a phase 1 study in patients with head and neck cancers and is currently being evaluated in combination with huCART-meso cells – cells manufactured using a patient’s own white blood cells, which are modified to target cancer cells or cells that help cancer to grow – in an investigator-sponsored study in patients with either pancreatic cancer or ovarian cancer. Beyond VCN-01, Theriva Biologics is also developing SYN-004 (ribaxamase), which is aligned with the company’s oncology focus and seeks to mitigate adverse outcomes for patients who will undergo bone marrow transplant (allogeneic hematopoietic cell transplantation) to treat hematologic cancers. 80% to 90% of these patients will be treated with an intravenous β-lactam antibiotic, and this antibiotic treatment has been strongly associated with increased incidence and severity of acute graft-vs-host disease (aGVHD), vancomycin-resistant Enterococci (VRE) infection and Clostridioides difficile infection (CDI). Preventing one or all of these outcomes by SYN-004 co-administration may significantly improve treatment outcomes and reduce patient mortality. VCN-01 Receives Fast Track Designation By The U.S. FDA Theriva Biologics achieved a significant milestone as the FDA granted Fast Track Designation (FTD) to VCN-01. This designation, in combination with gemcitabine and nab-paclitaxel – standard-of-care chemotherapy drugs – is aimed at improving progression-free survival and overall survival in patients with metastatic pancreatic cancer. This recognition underscores Theriva Biologics' commitment to advancing cancer treatment and the potential of VCN-01 in this field. Pancreatic cancer is one of the leading causes of cancer death globally. The increasing incidence of this cancer across the U.S. and other parts of the world is one of the factors driving the need for drugs used in its treatment. According to research published by Fortune Business Insights, the global pancreatic cancer treatment market size was $2.86 billion in 2023 and is projected to grow from $3.30 billion in 2024 to $10.69 billion by 2032. Attaining FTD is a seminal achievement for pharmaceutical drug companies, as the designation is designed to help treatments reach patients faster by facilitating the development and expediting the review of therapies with the potential to treat serious conditions and fill an unmet medical need. Benefits of FTD to programs include early and frequent interactions with the FDA during the clinical development process, and if relevant criteria are met, the FDA may also review portions of a marketing application before the sponsor submits the complete application. Regarding Theriva Biologics receiving the FTD, Shallcross said, “The FDA’s decision to grant FTD to VCN-01 highlights the urgent need for new treatment options for PDAC, which accounts for the 4 th highest cause of cancer-associated deaths in the US and Europe. VIRAGE, our Phase 2b trial evaluating VCN-01 in metastatic PDAC continues to progress, with enrollment expected to be completed in the third quarter of 2024. FTD is an important step that furthers our ability to expedite the review of and build upon the compelling clinical data that underscores VCN-01’s multiple modes of action and therapeutic potential in combination with chemotherapy or immunotherapy. We will continue to deliver on our mission to advance new therapeutic options for these patients.” Based on the strength of the science and its relevance, VIRAGE was accepted for presentation as a trial-in-progress poster at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, IL, from May 31-June 4. The Path Forward Theriva Biologics' approach to cancer treatment differentiates it from its peers, potentially placing the company in a unique market position. As incidences of pancreatic cancer continue to rise globally, drug treatment options, such as VCN-01, will likely rise in demand. With VCN-01 receiving FTD from the U.S. FDA, this milestone speaks to the drug's efficacy and long-run potential. As such, the benefit that Theriva Biologics provides and the value proposition the firm espouses could continue to grow and have increased industry resonance. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

June 07, 2024 08:45 AM Eastern Daylight Time

Image

1 2 3 4 5 ... 3602